Mortality and use of angiotensin converting enzyme inhibitors in Covid 19 disease – a systematic review

Introduction

An epidemic of viral disease caused by a new Coronavirus, Sars-Cov-2, is currently underway in most regions of the world. There is interest concerning angiotensin converting enzyme inhibitors (ACEi) use in this context, since the vims appears to interact with the angiotensin converting enzyme type 2 (ACE2)¹.

Although ACEi and angiotensin receptor blockers are sometimes evaluated together, they do not have a common mechanism of action, and there are data indicating that they may not share clinical results in the context of the current Sars-Cov-2 epidemic².

In the present report, a systematic review was carried out, looking at published reports studying the association between ACEi use and mortality in patients with Covid-19, the disease caused by the new Coronavirus. The aim of the study was to use currently available data to tentatively evaluate if a relation exists between ACEi use and patient mortality in this context.

Methods

Search strategy

The study started with a search on Medline (PubMed) database, using the query “Covid-19” AND “ACE inhibitor” AND “mortality”. The search took place on May 9, 2020, and no articles were excluded based on publication date. The query resulted in 4 articles being found. A further search was carried out in a second database, ISI Web of Knowledge, with the same query, in the same date, yielding 2 articles (Figure 1, prepared in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement). Further additional studies were identified in other relevant sources (Figure 1).

• Download figure
• Open in new tab

Figure 1. Flow diagram of studies selection.

Results

A total of 19 articles were identified and selected for further study. One report had no fatalities in one of the groups, making these data unsuitable to be used by the meta-analysis software⁴. One further report did not include the number of deaths⁵. A British report lacked specific data on ACEi⁶. Other articles also failed to include the data of interest for the present purpose^7,8 – and this was the only reason to exclude reports from entering meta-analyses.

Four studies were used to produce the meta-analyses^2,9–11 (Figure 2). These four studies involved a total number of 1.423 patients treated with ACEi and 11.868 not treated with ACEi. The main results concerning ACEi use and mortality are presented in Table 1.

• Download figure
• Open in new tab

Figure 2. Meta-analysis comparing mortality in patients with Covid-19 disease treated or not treated with angiotensin converting inhibitors (ACEi). For references see text. Cl – confidence interval.

Significant heterogeneity was seen concerning mortality associated to the use of ACEi in the context of Covid-19 disease. One report showed decreased mortality associated to ACEi use, but this finding was not confirmed by the three other studies. No significant difference in mortality was seen in the meta-analysis (random effects; odds ratio, 0.93; 95% confidence interval [Cl], 0.44 to 1. 94; P = 0.84; I squared 90.72; Figure 2).

When compared to mortality in patients treated with angiotensin receptor blockers, mortality of patients treated with ACEi was not significantly different, although a trend was noted to exist (odds ratio, 0.74; 95% confidence interval [Cl], 0.41 to 1.34; P = 0.32,I squared 78.7) (Figure 3). The population studied in the report showing decreased mortality associated to ACEi use had a mean age under 50 years, whereas two reports had a mean or median patient age over 60 years (Table 1). Overall mortality also differed substantially when the four reports were compared, with mortality rates of 5.78% and 20.99% as extreme values (Table 1).

• Download figure
• Open in new tab

Figure 3. Meta-analysis comparing mortality in patients under angiotensin converting inhibitors (ACEi) or angiotensin receptor blockers (ARB) in patients with Covid-19 disease. For references see text. Cl – confidence interval.

The four reports used for the meta-analyses were evaluated for global quality, and the results are presented in the Supplementary Table 3.

Discussion

In the present report, a systematic review was carried out concerning the use of ACEi and a possible association to a change in mortality in Covid-19 disease. Only observational reports were found, with no clinical trial data. Until further data are available, it can be said that ACEi use has not been shown to increase mortality in the setting of Covid-19 disease.

As shown in Figure 2, the larger report to date, by Mehra et al., shows a significant decrease in mortality in association to ACEi use – unlike what happens in the same report with the use of angiotensin receptor blockers². Among reports describing favorable results for ACEi in the context of Covid-19, Ip et al. also stated that mortality rates were lower for hypertensive patients prescribed ACEi⁵.

Rossi et al. indicate a numerical increase in mortality with previous ACEi use, although the authors carried out a data adjustment for age, sex and Charlson Comorbidity Index, and state that “previous use of ACE inhibitors has no effect on risk of death (HR 0.97,95% Cl 0.69 to 1.34)”¹¹. Richardson et al. also show a numerical increase in mortality with ACEi use¹⁰. The reports published so far have conflicting results, and the reasons for the different results are not clear for the moment, but they could include differences in the study methods and/or in the studied populations¹² (perhaps also differences in previous exposures to a Coronavlrus).

Donoghue et al. showed that conversion of angiotensin I to angiotensin 1–9 by ACE2 was not inhibited by either lislnopril or captopril¹³. Tlpnis et al. reported similar results¹⁴. Shahid et al. hypothesize that hydrogen bonds are formed between between ACE2 and either ACEi or angiotensin receptor blockers¹⁵, whereas Lobo-Galo et al. hypothesize that captopril is a potential ligand for the SARS-CoV-2 main protease (3CLpro)¹⁶. Angiotensin I has a molecular weight of 1296.5 g/mol, corresponding to a molecular formula C62H89N17O14 (PubChem Database). Angiotensin I is therefore several orders of magnitude smaller than a Coronavirus. It may happen that ligands (such as ACEi molecules) that are unable to impede the enzymatic action of ACE2 may nevertheless be able to decrease the binding of a much larger structure, as Is the case of a coronavirus. This hypothesis could help to explain at least part of the data by Mehra ef al.² or of Ip et al.⁵.

The age difference seen in the populations studied by the various authors could modulate the effects of ACEi use in this context. Aging is associated to an increased low grade chronic inflammatory state¹⁷, decreased muscle mass, increased adiposity and a state of immune dysregulation. Changes in multiple mechanisms have been seen with aging, resulting in inflammation¹⁷. Both tumor necrosis factor-alpha and interleukin-6 have been shown to predict mortality in the elderly¹⁸. In Covld-19 disease, an increase in inflammatory mediators is seen in patients with more severe disease¹⁹. Increasing age is a known major factor for mortality in Covid-19 disease²,¹⁹.

The present data lead to the hypothesis that ACEi use could act as a protective factor in younger Covid-19 patients, but not in older patients, perhaps with a background of low grade inflammation and immune dysregulation – a hypothesis perhaps to be explored in clinical trials. Stated in other terms, the possible protective effect of ACEi in this context could be limited to younger populations with not very high mortality rates and not to older patient populations with high or very high mortality rates.

Limitations

Limitations of the present report are very important. Not only are all the data reviewed of an observational character, but significant heterogeneity exists when the different reports are compared (as shown in Table 1). Several types of bias could exist in the reports under study.

Conclusions

In conclusion, significant heterogeneity was seen in observational reports concerning the use of ACEi and patient mortality in the context of Covid-19 disease. For the moment, it would appear reasonable not to withdraw ACEi from patients currently treated with these drugs. The data now presented argue in favor of carrying out clinical trials studying ACEi in Covid-19 patients, perhaps to explore the hypothesis that ACEi use has a protective effect in populations with a mean age under 50 years, but not necessarily in those with a mean age over 60 years and with high or very high mortality rates.

Funding information

No funding received for the preparation of this text.

Conflict of interest statement

None to report.